TTRX (Turn Therapeutics) ROCE %: -50.67% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TTRX Turn Therapeutics Inc TTRX
11 GF Score
Price $7.48
View Full Analysis

What is Turn Therapeutics ROCE %?

Turn Therapeutics TTRX +0.54% 11 ROCE % is -50.67% as of Mar. 2026. GuruFocus rates TTRX with a GF Score™ of 11/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Turn Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -50.67%.

Turn Therapeutics  (NAS:TTRX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Turn Therapeutics ROCE % Related Terms

Turn Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Turn Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Turn Therapeutics ROCE % Chart

Turn Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
ROCE %
-151.44 -125.45 -156.24

Turn Therapeutics Quarterly Data
Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only -114.84 -167.22 -291.16 -215.41 -50.67
TTRX
11GF Score
Turn Therapeutics Inc TTRX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Turn Therapeutics ROCE % Calculation

Turn Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-5.859/( ( (2.049 - 0.708) + (12.162 - 6.003) )/ 2 )
=-5.859/( (1.341+6.159)/ 2 )
=-5.859/3.75
=-156.24 %

Turn Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-4.984/( ( (12.162 - 6.003) + (18.644 - 5.131) )/ 2 )
=-4.984/( ( 6.159 + 13.513 )/ 2 )
=-4.984/9.836
=-50.67 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -50.67% mean?
Turn Therapeutics (TTRX) has a ROCE % of -50.67% as of Mar. 2026.
Is Turn Therapeutics' ROCE % too high?
Turn Therapeutics' current ROCE % is -50.67%. Overall, Turn Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Turn Therapeutics' ROCE % compare to IRD and VRXA?
Turn Therapeutics' ROCE % of -50.67% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Turn Therapeutics's current ROCE % is -50.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Turn Therapeutics stock overvalued right now?
Turn Therapeutics (TTRX) has a current ROCE % of -50.67%. The current ROCE % is -50.67%. Turn Therapeutics' overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Turn Therapeutics (TTRX), the current ROCE % is -50.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Turn Therapeutics Business Description

Address 250 North Westlake Boulevard, Suite 210, Westlake Village, CA, USA, 91362
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
11GF Score

Get the complete analysis for TTRX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.48
Price